Janssen Pharmaceutical Inc.
NEWS
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
The FDA recently approved the combination of Imbruvica-Rituximab for treating chronic lymphocytic leukemia. Here’s everything you need to know.
The Breakthrough Therapy Designation is based on data from a Phase I trial of JNJ-6372 alone and in combination with lazertinib, a novel third-generation EGFR TKI in adults with advanced NSCLC.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
It was a very busy week for clinical trial news. Here’s a look.
Janssen Pharmaceutical said 79% of patients in a late-stage trial showed a clinical response to the medication and 67% were in clinical remission.
The biotech Hotbed known as Pharm Country, which includes New Jersey, Connecticut, New York Pennsylvania and Rhode Island, is an area of rapid growth and change.
Latest approval for apalutamide could benefit a population of more than 100,000 people living with mHSPC across Europe.
JOBS
IN THE PRESS